期刊
CURRENT HEMATOLOGIC MALIGNANCY REPORTS
卷 15, 期 4, 页码 343-349出版社
CURRENT MEDICINE GROUP
DOI: 10.1007/s11899-020-00586-1
关键词
Chronic lymphocytic leukaemia; B cell receptor inhibitors; Venetoclax; Combination strategies; Indefinite treatment; Time-fixed therapy
Purpose of Review The treatment landscape for chronic lymphocytic leukaemia (CLL) is rapidly evolving, with several targeted agents recently approved. These compounds have dramatically changed the natural history of the disease. Recent Findings However, with the array of effective therapies commercially available, the challenge is to define tailored treatment strategies able to realize a balance between treatment efficacy and toxicity or tolerance. New algorithms of treatment are being developed, and it appears that minimal residual disease (MRD) directed therapy will become the norm in the future. Clinical trials are looking at various combinations of novel therapies given with a defined, fixed-period of treatment based on MRD analysis. This approach enables patients to have a period of treatment-free remission instead of continuous therapy. In this review, we summarize this evolution of targeted therapies in CLL.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据